LIPO Apigenin – Powdered Liposomal Apigenin

Description

LIPO Apigenin™ is a sustained-released liposomal delivery system that provides superior absorption of Apigenin in easy-to-swallow capsules.

Our process encapsulates and delivers Apigenin intracellularly in its complete form where it can be absorbed and utilized rather than being destroyed in the stomach.

Apigenin is a naturally-occurring bioactive plant polyphenol with antioxidant, anti-inflammatory, antiviral, and neuroprotective properties. Increasing Apigenin in the body has been shown to enhance cognition, stimulate the immune system, diminish oxidative stress and improve cellular detoxification.

LIPO Apigenin™ offers advanced support for:

▸  Neuroprotection

▸  Inflammation

▸  Blood glucose metabolism

▸  Nervous system function

Apigenin – a powerful new anti-aging and performance-enhancing supplement

Apigenin is a naturally-occurring bioactive plant polyphenol with antioxidant, anti-inflammatory, antiviral, and neuroprotective properties. However, recent research has shown that Apigenin also has a powerful, new anti-aging and performance-enhancing benefit as well.

Senescent cells increase CD38 and decrease NAD+ levels

As we age, we accumulate senescent or “zombie” cells, cells that have reached their limit of cell division and would normally be swept away and replaced by younger cells. Instead, these cells hang around and begin to secrete toxins called SASP factors which increase systemic inflammation, one of the hallmarks of aging.

The rising levels of inflammation cause an increase in an enzyme called CD38, a big consumer of NAD+, causing systemic NAD+ levels to drop.

“Our data suggest a link between cellular senescence and NAD+ decline in which SASP-mediated upregulation of CD38 can disrupt cellular NAD+ homeostasis.” (1)

Fighting declining levels of NAD+ with Apigenin

Apigenin prevents excessive loss of NAD+ by reducing the amount of circulating CD38, allowing NAD+ stores to remain at higher, more youthful levels.

We showed that the activity of CD38, but not PARP, increases in several tissues during the aging process, and that genetic ablation of CD38 protects against age-related NAD+ decline and, mitochondrial dysfunction.” (2)

Inhibition of CD38 raises NAD+ levels, increases Lifespan, and Healthspan in mice

Studies have found that lowering CD38 levels (using a CD38 inhibitor called 78c) not only increased NAD+ levels but also improved mitochondrial function and endurance performance.

“Deletion of PARP-1 or CD38, or the inhibitor of CD38 or PARP-1, improves mitochondrial function and endurance performance in mice.” (4)

“aged mice (2 years old) had lower tissue NAD+ levels, and worse glucose tolerance compared with younger mice. 78c promoted a significant increase in NAD+ levels in tissues of aged mice” (4)

Apigenin may decrease CD38 and senescent (zombie) cells

This study found Apigenin decreases senescent cells, resulting in less CD38.

Apigenin reduced senescence-associated activity and promoted cell growth

Apigenin also increased the activation ratio of silent information regulator 1 (SIRT1), and inhibited CD38 activity in a concentration-dependent manner.

Our findings suggest that apigenin is a promising phytochemical for reducing the impact of senescent cells (5)

As with other bioflavonoids, the bioavailability of Apigenin is extremely low   (Source).

Poor aqueous solubility, chemical instability, and low oral bioavailability significantly limit its applications.  (Source)

“oral bioavailability of APG is relatively low because of its low aqueous solubility (2.16 μg/mL in water), [2] which has severely limited its further clinical development. Therefore, it is necessary to develop a novel formulation using advance strategies to improve APG oral bioavailability”

Under the Biopharmaceutics Classification System, Apigeninis classified as a class IV compound (low solubility, low permeability). (Source)

A recent study focusing on establishing apigenin as a potential chemotherapeutic agent for alleviating colorectal cancer reports the development of a stable liposomal nanocarrier with high encapsulation of the hydrophobic flavone apigenin for enhanced chemotherapeutic effects.

“Apigenin liposomes bypass the hurdles posed by apigenin as a chemotherapeutic due to its high hydrophobicity. The enhanced pharmacological activity of apigenin has been assigned to its ability to interact and subsequently influence membrane properties which also resulted in optimal yield of a stable, rigidified, non-leaky nano-carrier with ideal release kinetics.” (6)